Literature DB >> 11015145

Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody.

P A Kozlowski1, R M Lynch, R R Patterson, S Cu-Uvin, T P Flanigan, M R Neutra.   

Abstract

Weck-Cel sponges were examined for suitability as an absorbent material for nontraumatic collection of rectal secretions in humans. Sponges were tested in vitro and determined by quantitative enzyme-linked immunosorbent assay (ELISA) to be capable of releasing 100% of absorbed albumin and all immunoglobulin subtypes after treatment with detergent-supplemented buffer. Protein composition in rectal secretions collected from normal women with dry sponges (DS) or with sponges previously softened by moistening with saline (MS) was subsequently compared. DS secretions showed evidence of contamination with blood and interstitial fluid-derived albumin, immunoglobulin G (IgG), and monomeric IgA. MS secretions appeared to represent local mucosal secretions more accurately because they contained negligible blood, a greater percentage of secretory IgA within the total IgA, and both lower albumin/IgG ratios and more dramatic alterations in IgG subclass distribution compared with corresponding serum. Anti-HIV IgG, IgM, IgA, and antibodies with secretory component could be demonstrated by ELISA in rectal secretions collected with moist sponges from 8 of 8, 1 of 8, 5 of 8, and 3 of 8 HIV-infected women, respectively. The data show that Weck-Cel sponges, if premoistened, can be used to collect rectal fluids nontraumatically and to obtain quantitative information about concentrations of immunoglobulins and specific antibodies on rectal mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015145     DOI: 10.1097/00126334-200008010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  74 in total

1.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

2.  Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Authors:  Nicholas J Mantis; Jana Palaia; Ann J Hessell; Simren Mehta; Zhiyi Zhu; Blaise Corthésy; Marian R Neutra; Dennis R Burton; Edward N Janoff
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

3.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

4.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.

Authors:  Diane L Bolton; Kaimei Song; Georgia D Tomaras; Srinivas Rao; Mario Roederer
Journal:  Vaccine       Date:  2016-12-29       Impact factor: 3.641

5.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

6.  A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques.

Authors:  Kara Jensen; Myra Grace Dela Pena; Robert L Wilson; Uma Devi K Ranganathan; William R Jacobs; Glenn Fennelly; Michelle Larsen; Koen K A Van Rompay; Pamela A Kozlowski; Kristina Abel
Journal:  Trials Vaccinol       Date:  2013-11-01

7.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Authors:  Marta L Marthas; Koen K A Van Rompay; Zachary Abbott; Patricia Earl; Linda Buonocore-Buzzelli; Bernard Moss; Nina F Rose; John K Rose; Pamela A Kozlowski; Kristina Abel
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

8.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

9.  Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts.

Authors:  Carla Donadoni; Cinzia Bisighini; Lorenza Scotti; Lorenzo Diomede; Marie Ngyen; Janin Nouhin; Lucia DeSantis; Antonella Zambon; Davide Ferrari; Giulia Gallotta; Giovanni Corrao; Gianfranco Pancino; Lucia Lopalco
Journal:  PLoS One       Date:  2010-03-29       Impact factor: 3.240

10.  Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.

Authors:  Smita S Iyer; Sailaja Gangadhara; Blandine Victor; Xiaoying Shen; Xuemin Chen; Rafiq Nabi; Sudhir P Kasturi; Michael J Sabula; Celia C Labranche; Pradeep B J Reddy; Georgia D Tomaras; David C Montefiori; Bernard Moss; Paul Spearman; Bali Pulendran; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.